spacer
home > pmps > spring 2017 > supply and demand
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Supply and Demand

The R&D of a new molecular entity (NME) is a constant battle and requires tradeoffs between the budget set by the organisation, product development goals, personnel available and the public health issues of the country. The total worldwide R&D expenditure of pharmaceutical and biotechnology companies increased from $108 billion in 2006 to $141 billion in 2015. Paul et al reported that:
  • Drug discovery and preclinical development account for 33% of the total cost per NME ($281 million)
  • Clinical development (Phase 1 to submission) represents 63% ($548 million)
  • Submission to launch costs 5% of the overall expenditures per NME ($44 million)
Discovery research lasts four and a half years; preclinical testing continues for a further year; the three clinical development phases take 1.5, 2.5 and 2.5 years respectively; and the phase from submission to launch requires another 18 months. The above is a clear testimonial of the significance of the whole clinical research process that accounts for the majority of the cost and time involved in bringing an innovation to market.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
With over 19 years of clinical research experience in global project management and CTS, Partha Chatterjee is Head of Clinical Research and Clinical Trial Supplies Management at SIRO Clinpharm. A postgraduate in Microbiology from the Institute of Science, India, he was one of the earliest members of the company and his knowledge and expertise have been pivotal in managing numerous key clinical trials across therapeutic areas such as oncology, nephrology, endocrinology and infectious diseases.
spacer
Partha Chatterjee
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

BioGenes Establishes Scientific Advisory Board

Berlin, Germany, December 12, 2017 / B3C newswire / -- BioGenes GmbH, specializing in ELISA development and production and a global leader in host cell protein (HCP) assay development, today announces the establishment of a Scientific Advisory Board which includes the following four renowned experts:
More info >>

White Papers

Nanoparticle Tracking Analysis. A Review of Applications and Usage in the Analysis of Exosomes and Microvesicles

NanoSight

The study of exosomes and other cell-derived microvesicles is an area of rapidly growing importance and the subject of intense interest and research. The previous lack of suitable methods for their detection, analysis, enumeration and phenotyping is proving to be a significant limitation in these studies. This mini-review shows the degree to which the technique of Nanoparticle Tracking Analysis (NTA) is helping to address these problems.
More info >>

 
Industry Events

IRT Europe Summit

10-11 April 2018, The Hotel Brussels, Belgium

New clinical trial regulations are requiring sponsors to keep tighter oversight than ever before from audit trails to tracking system changes resulting in high costs and trial delays. IRT Europe explores implementation best practices and how interactive response technologies can be utilised to improve supply chain planning and optimise clinical trials.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement